Advertisement
U.S. markets open in 44 minutes
  • S&P Futures

    5,305.25
    -3.00 (-0.06%)
     
  • Dow Futures

    40,150.00
    +6.00 (+0.01%)
     
  • Nasdaq Futures

    18,490.50
    -13.25 (-0.07%)
     
  • Russell 2000 Futures

    2,138.60
    +0.20 (+0.01%)
     
  • Crude Oil

    82.68
    +1.33 (+1.63%)
     
  • Gold

    2,227.70
    +15.00 (+0.68%)
     
  • Silver

    24.67
    -0.08 (-0.33%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.2260
    +0.0300 (+0.71%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.10%)
     
  • USD/JPY

    151.2820
    +0.0360 (+0.02%)
     
  • Bitcoin USD

    70,509.84
    +478.95 (+0.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,949.27
    +17.29 (+0.22%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Masimo Third Quarter 2022 Earnings: Beats Expectations

Masimo (NASDAQ:MASI) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$549.3m (up 79% from 3Q 2021).

  • Net income: US$37.9m (down 34% from 3Q 2021).

  • Profit margin: 6.9% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses.

  • EPS: US$0.72 (down from US$1.05 in 3Q 2021).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Masimo Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 13% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Masimo (1 shouldn't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement